NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Biocon Q3 FY26: Revenue Up 9% to ₹4,173 Cr; Biologics Unit to Become 100% Subsidiary
Biocon Limited reported a 9.2% YoY increase in consolidated revenue to ₹41,730 million for Q3 FY26, driven by steady growth in Biosimilars and Generics. Despite the revenue growth, the company reported a consolidated net loss of ₹518 million, primarily due to a significant exceptional loss of ₹2,934 million. A key strategic development is the Board's approval to acquire the remaining ~2% stake in Biocon Biologics Limited (BBL) through a share swap, which will make BBL a wholly-owned subsidiary. While the bottom line was impacted by one-offs, the profit attributable to shareholders remained positive at ₹1,438 million.
முக்கிய அம்சங்கள்
Consolidated revenue from operations grew 9.2% YoY to ₹41,730 million in Q3 FY26.Biosimilars segment remains the largest contributor with revenue of ₹24,967 million, up from ₹22,890 million YoY.Reported a consolidated net loss of ₹518 million for the quarter after accounting for ₹2,934 million in exceptional items.Board approved the acquisition of the final ~2% stake in Biocon Biologics via preferential allotment of Biocon Ltd shares.Generics segment revenue increased to ₹8,513 million compared to ₹6,864 million in the same quarter last year.
👀 கவனிக்க வேண்டியவை
Investors should focus on the long-term benefits of the full integration of Biocon Biologics, though the immediate impact of equity dilution from the share swap needs to be assessed. The core operational growth in Biosimilars is encouraging, but bottom-line volatility remains a key watchpoint.
Alembic Ltd Q3 Revenue Up 28% YoY to ₹74.34 Cr; API Segment Revenue Doubles
Alembic Limited reported a consolidated revenue of ₹74.34 crore for Q3 FY26, marking a 28.3% growth compared to ₹57.92 crore in the same period last year. Net profit (including share of associates) stood at ₹60.13 crore, a slight decline from ₹65.39 crore YoY, impacted by higher construction costs and a ₹1.43 crore provision for new labour codes. The API segment showed robust growth, with revenue surging 116% YoY to ₹13.50 crore. However, a significant negative swing in Other Comprehensive Income led to a total comprehensive loss of ₹56.84 crore for the quarter.
முக்கிய அம்சங்கள்
Consolidated Revenue from Operations increased 28.3% YoY to ₹74.34 crore.API business revenue surged 116% YoY to ₹13.50 crore from ₹6.25 crore.Real Estate segment revenue grew to ₹60.84 crore compared to ₹51.67 crore in the previous year's quarter.Net Profit after tax (including associate share) declined 8% YoY to ₹60.13 crore.Company made a provision of ₹143.72 lakhs towards the implementation of four new Labour Codes.
👀 கவனிக்க வேண்டியவை
Investors should focus on the strong momentum in the API segment and steady real estate performance, while remaining cautious about the volatility in total comprehensive income caused by investment valuation changes.
BIL Vyapar CoC Approves Resolution Professional Appointment Amid Insolvency Process
BIL Vyapar Limited, formerly known as Binani Industries Limited, has announced the outcome of its first Committee of Creditors (CoC) meeting following its entry into the Corporate Insolvency Resolution Process (CIRP). The CoC has officially approved the appointment of Ms. Rachna Jhunjhunwala as the Resolution Professional to oversee the company's affairs. Additionally, the committee ratified expenses related to public announcements and the remuneration for the Interim Resolution Professional. The company has been under the management of an insolvency professional since the NCLT order dated November 13, 2025.
முக்கிய அம்சங்கள்
Company is currently under Corporate Insolvency Resolution Process (CIRP) per NCLT order dated November 13, 2025.First CoC meeting held on December 19, 2025, with e-voting concluding on December 26, 2025.Ms. Rachna Jhunjhunwala appointed as the Resolution Professional (RP) for the insolvency process.CoC ratified and approved all expenses related to the public announcement and IRP remuneration under the IBC 2016.
👀 கவனிக்க வேண்டியவை
Investors should exercise extreme caution as insolvency proceedings often lead to significant equity dilution or delisting of the company. Monitor future disclosures regarding the resolution plan to assess any potential recovery value for shareholders.
BIL Vyapar Appoints Rachna Jhunjhunwala as Resolution Professional in First CoC Meeting
BIL Vyapar Limited, formerly known as Binani Industries, has reported the outcomes of its first Committee of Creditors (CoC) meeting following its entry into the Corporate Insolvency Resolution Process (CIRP). The CoC has officially approved the appointment of Ms. Rachna Jhunjhunwala as the Resolution Professional (RP), succeeding the Interim Resolution Professional. The committee also ratified the expenses incurred for public announcements and the remuneration for the outgoing IRP. The company has been under insolvency proceedings since the NCLT order dated November 13, 2025.
முக்கிய அம்சங்கள்
Appointment of Ms. Rachna Jhunjhunwala as Resolution Professional (RP) approved by the CoC.Ratification of expenses related to Public Announcement and other IBC 2016 costs.Approval of remuneration for the Interim Resolution Professional (IRP), Mr. Subodh Kumar Agrawal.Company entered CIRP following an NCLT order on November 13, 2025, with the order received on November 21, 2025.
👀 கவனிக்க வேண்டியவை
Investors should be aware that the company is in insolvency, which typically results in significant risk to equity holders. Monitor the resolution process closely as equity value is often severely diluted or wiped out in final resolution plans.
BIL Vyapar Issues Revised Form G for CIRP; EOI Submission Deadline Feb 19, 2026
BIL Vyapar Limited, formerly known as Binani Industries, has issued a revised Form G inviting Expressions of Interest (EOI) under the Corporate Insolvency Resolution Process (CIRP). The company is currently in a distressed state, reporting zero operational revenue and only Rs. 2.51 lakh in other income for FY 2024-25. The insolvency process follows an NCLT order from November 2025, with the company currently having no employees. Prospective resolution applicants have until February 19, 2026, to submit EOIs, with final resolution plans expected by April 7, 2026.
முக்கிய அம்சங்கள்
Last date for receipt of Expression of Interest (EOI) is February 19, 2026.Final date for submission of Resolution Plans is set for April 7, 2026.FY 2024-25 financials show zero revenue from operations and zero employees.Company is under CIRP managed by Interim Resolution Professional Subodh Kumar Agrawal.Provisional list of resolution applicants to be issued by February 26, 2026.
👀 கவனிக்க வேண்டியவை
Equity shareholders should exercise extreme caution as insolvency proceedings often result in total capital loss or delisting. It is advisable to monitor the resolution process for any updates on the company's future viability or liquidation.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Cantabil Q3 FY26 PAT Jumps 31% to ₹45.1 Cr; Revenue Up 19% YoY
Cantabil Retail India Limited reported a robust performance for Q3 FY26, with revenue growing 19% YoY to ₹264.4 crore and PAT increasing 31% to ₹45.1 crore. The company achieved a healthy 9-month same-store sales growth (SSG) of 6.3% and expanded its retail footprint to 646 stores across 8.82 lakh square feet. Management reaffirmed its 'Vision 2027' goal of reaching ₹1,000 crore in revenue by FY27, supported by GST rationalization benefits and consistent gross margins of 58-59%. The EBITDA margin for the quarter improved significantly to 36% from 32.6% in the previous year.
முக்கிய அம்சங்கள்
Q3 FY26 PAT surged 31% YoY to ₹45.1 crore with EBITDA margins improving to 36%.9-month FY26 revenue grew 20% to ₹599.1 crore, supported by a 6.3% same-store sales growth (SSG).Total store network reached 646 outlets, with revenue per square foot for mature stores at ₹1,018 for the quarter.Management targets ₹1,000 crore revenue by FY27 with sustainable gross margins of 58-59%.Franchise stores now account for 131 outlets (20% of total), operating on a fixed commission model of 27-28%.
👀 கவனிக்க வேண்டியவை
Investors should note the strong margin expansion and consistent SSG as indicators of operational efficiency and brand strength. The clear roadmap to ₹1,000 crore revenue by FY27 suggests continued growth potential, making it a positive outlook for long-term holders.
Concord Biotech Q3 Revenue Up 14% to Rs 278 Cr; EBITDA Margins Impacted by Expansion Costs
Concord Biotech reported a 14% YoY revenue growth in Q3FY26, reaching Rs 278 crore, primarily driven by a 24% surge in the API segment. However, PAT declined by 16% YoY to Rs 64 crore due to commercialization expenses for the new injectable facility and setup costs for its US subsidiary, Stellon Biotech. EBITDA margins compressed to 35.6% from 40.1% a year ago, though normalized margins remain healthy at approximately 40%. The company achieved a significant milestone by receiving WHO-GMP certification for its injectable plant, paving the way for domestic market entry.
முக்கிய அம்சங்கள்
Q3FY26 Revenue grew 14% YoY to Rs 278 crore, led by robust 24% growth in the API segment.EBITDA margins stood at 35.6%, impacted by one-time setup costs; normalized margins are at ~40%.Received WHO-GMP certification for Unit 4 (Injectable facility), enabling domestic brand launches.Established US subsidiary Stellon Biotech Inc. to create a direct commercial footprint in the US market.Appointed Raviraj Karia as the new Chief Financial Officer (CFO) with 23+ years of experience.
👀 கவனிக்க வேண்டியவை
Investors should monitor the ramp-up of the new injectable facility and the performance of the US subsidiary, as these are the primary drivers for future growth despite current margin pressure. The long-term outlook remains positive due to specialized fermentation capabilities and global expansion.
Panacea Biotec Q3 Results: Consolidated Net Profit at ₹389 Lakh; Standalone Loss Widens
Panacea Biotec reported a consolidated net profit of ₹389 lakh for the quarter ended December 31, 2025, a slight decline from ₹444 lakh in the previous year. Consolidated revenue from operations grew marginally to ₹16,519 lakh compared to ₹16,349 lakh YoY. However, the standalone business faced significant pressure, reporting a net loss of ₹736 lakh against a profit of ₹965 lakh in the same period last year. The company continues to benefit from exceptional income, including a ₹858 lakh settlement with Apotex Inc. and deferred consideration from previous brand sales.
முக்கிய அம்சங்கள்
Consolidated revenue from operations increased 1.04% YoY to ₹16,519 lakh.Formulations segment EBIT turned positive at ₹906 lakh compared to a loss of ₹758 lakh in Q3 FY25.Vaccines segment reported a loss of ₹257 lakh at the EBIT level for the quarter.Exceptional income of ₹1,679 lakh recognized in 9M FY26, including ₹858 lakh from a settlement with Apotex Inc.Standalone net loss for 9M FY26 widened significantly to ₹2,970 lakh from ₹284 lakh in 9M FY25.
👀 கவனிக்க வேண்டியவை
Investors should exercise caution as the company remains loss-making on a 9-month consolidated basis despite the quarterly profit. Monitor the vaccines segment's recovery and the company's ability to generate consistent operational cash flow without relying on exceptional items.
Panacea Biotec Q3 FY26 Results: Consolidated Net Profit at ₹3.89 Cr; Revenue Grows 1% YoY
Panacea Biotec reported a consolidated net profit of ₹3.89 crore for Q3 FY26, a slight decline from ₹4.44 crore in the same quarter last year. Consolidated revenue from operations grew marginally by 1% YoY to ₹165.19 crore. For the nine-month period, the company remains in a net loss of ₹6.16 crore, though this narrowed from a loss of ₹6.73 crore in the previous year. The results were significantly supported by an exceptional income of ₹16.79 crore in the 9M period, including a settlement with Apotex Inc.
முக்கிய அம்சங்கள்
Consolidated Q3 revenue reached ₹165.19 crore, a marginal 1% increase over the previous year's ₹163.49 crore.Formulations segment profit improved significantly to ₹9.06 crore from a loss of ₹7.58 crore in Q3 FY25.Vaccines segment reported a loss of ₹2.57 crore for the quarter despite revenue of ₹99.24 crore.Exceptional income of ₹16.79 crore for 9M FY26 includes ₹8.58 crore from a settlement with Apotex Inc.Standalone net loss stood at ₹7.36 crore for Q3 FY26, compared to a profit of ₹9.65 crore in Q3 FY25.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's ability to sustain operational profitability without relying on exceptional items and brand sale deferrals. While the turnaround in the formulations segment is positive, the core vaccine business remains under pressure.
Concord Biotech Approves Q3 FY26 Results; Appoints New Company Secretary
Concord Biotech's Board of Directors approved the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The statutory auditors, BSR & Co. LLP, issued a limited review report with an unmodified opinion, suggesting no major accounting concerns. Additionally, the company appointed Mr. Paritosh Trivedi as the new Company Secretary and Compliance Officer effective February 11, 2026. This appointment fills a key managerial personnel (KMP) role to oversee corporate governance and regulatory filings.
முக்கிய அம்சங்கள்
Board approved unaudited financial results for the third quarter and nine months ended December 31, 2025.Statutory auditors M/s. BSR & Co. LLP issued a Limited Review Report with an Unmodified Opinion.Mr. Paritosh Trivedi appointed as Company Secretary, Compliance Officer, and Nodal Officer.The new appointee brings 5 years of experience in corporate compliance across Textile, IT, and FMCG sectors.The board meeting concluded at 6:22 P.M. on February 11, 2026.
👀 கவனிக்க வேண்டியவை
Investors should examine the detailed financial tables once published to assess revenue and margin performance for Q3. The appointment of a new compliance officer is a routine administrative update and does not impact the company's fundamental value.
Bhartiya International Q3 Net Profit Surges 183% YoY to ₹6.68 Crore
Bhartiya International Limited (BIL) reported a strong financial performance for the quarter ended December 31, 2025, with standalone revenue growing 33.5% YoY to ₹312.67 crore. The standalone net profit witnessed a massive jump of 183%, reaching ₹6.68 crore compared to ₹2.36 crore in the same quarter last year. For the nine-month period, the company has already surpassed its full-year FY25 profit, recording a net profit of ₹32.20 crore. The results include a ₹1.87 crore impact from the implementation of New Labour Codes.
முக்கிய அம்சங்கள்
Standalone Revenue from Operations rose 33.5% YoY to ₹312.67 crore in Q3 FY26.Net Profit for the quarter surged 183% YoY to ₹6.68 crore from ₹2.36 crore.Basic EPS for the quarter improved significantly to ₹5.07 from ₹1.93 YoY.9-month FY26 Net Profit of ₹32.20 crore has already exceeded the full FY25 profit of ₹21.15 crore.Employee benefit expenses include a ₹1.87 crore impact due to New Labour Code implementation.
👀 கவனிக்க வேண்டியவை
The company is demonstrating strong growth momentum with 9-month profits already exceeding the previous full year's performance. Investors should maintain a positive outlook while monitoring the impact of rising material costs and labor code changes on operating margins.
SBI to Seek Shareholder Approval for Related Party Transactions Exceeding ₹5,000 Crore
State Bank of India (SBI) has called for an Extraordinary General Meeting (EGM) on March 27, 2026, to seek shareholder approval for material related party transactions for FY 2026-27. The bank expects transactions with subsidiaries like SBI Life and SBI Cards to exceed the materiality threshold of ₹5,000 crore or 10% of annual consolidated turnover. These transactions include distribution commissions, investment in debt securities, and various banking services. The move is a regulatory requirement to ensure transparency in intra-group dealings and will be conducted on an arm's length basis.
முக்கிய அம்சங்கள்
EGM scheduled for March 27, 2026, to approve transactions for the financial year 2026-27.Materiality threshold for transactions set at ₹5,000 crore or 10% of annual consolidated turnover.Major related parties include SBI Life Insurance, SBI Cards, SBI Payment Services, and Yes Bank.Transactions cover distribution commissions, repo/reverse repo, and purchase/sale of government securities.All proposed arrangements are mandated to be carried out on an arm's length basis per SEBI regulations.
👀 கவனிக்க வேண்டியவை
This is a routine regulatory compliance procedure for a large banking conglomerate; investors should view this as standard corporate governance with no immediate impact on stock valuation.
ESAB India Declares Second Interim Dividend of Rs 25 Per Share; Record Date Feb 14
ESAB India Limited has declared a second interim dividend of Rs 25 per equity share for the financial year 2025-26, representing a 250% payout on its face value of Rs 10. The total financial outflow for this dividend distribution is estimated at Rs 38.48 crore. The company has fixed February 14, 2026, as the record date to determine eligible shareholders. The dividend is scheduled to be paid to shareholders on or before March 6, 2026.
முக்கிய அம்சங்கள்
Second interim dividend of Rs 25 per equity share (250% of face value) declared.Total dividend payout amounts to Rs 38,48,25,500 for the financial year 2025-26.Record date for eligibility is February 14, 2026.Payment to be completed on or before March 6, 2026.
👀 கவனிக்க வேண்டியவை
Investors interested in the dividend should ensure they hold the shares before the ex-dividend date to be eligible for the Rs 25 per share payout. The substantial dividend reflects the company's healthy cash flow and commitment to shareholder returns.
ESAB India Q3 Net Profit Up 6.5% YoY to ₹43 Cr; Declares ₹25 Interim Dividend
ESAB India reported a steady performance for Q3 FY26 with a 6.5% YoY increase in net profit to ₹43 crore. Total income grew 11.5% YoY to ₹379.9 crore, driven by its core fabrication technology segment. The company declared a second interim dividend of ₹25 per share, bringing the total interim dividend for the year to ₹50. Profits were slightly tempered by a one-time exceptional charge of ₹13.65 crore related to gratuity liability adjustments under the new Code on Wages.
முக்கிய அம்சங்கள்
Total income for Q3 FY26 rose 11.5% YoY to ₹379.9 crore from ₹340.8 crore.Net Profit after Tax stood at ₹43 crore, up from ₹40.4 crore in the same quarter last year.Declared a second interim dividend of ₹25 per equity share for the financial year 2025-26.Recognized an exceptional loss of ₹13.65 crore due to increased gratuity liability from the Code on Wages 2019.9M FY26 Net Profit reached ₹163.1 crore, a 27.5% increase over the ₹128 crore reported in 9M FY25.
👀 கவனிக்க வேண்டியவை
Investors should remain positive as the company demonstrates consistent revenue growth and a strong commitment to shareholder returns through dividends. The exceptional hit is a non-recurring regulatory adjustment and does not impact the core operational efficiency.
Triveni Turbine Q3 Revenue Up 24% to ₹6.24 Billion; PAT Dips 1% on Exceptional Charge
Triveni Turbine reported a strong 24% YoY revenue growth in Q3 FY26, reaching ₹6.24 billion, though PAT slightly declined by 1% to ₹917 million due to a ₹15.7 crore non-recurring wage code charge. While order bookings for the quarter fell 26% YoY due to timing issues with advances, the company maintains a robust domestic enquiry pipeline across steel, cement, and sugar sectors. The US subsidiary reported a loss of ₹21.7 crore for the nine-month period, but management expects a recovery in Q4 and FY27 driven by new products like heat pumps and MVRs.
முக்கிய அம்சங்கள்
Q3 FY26 Revenue grew 24% YoY to ₹6.24 billion, while EBITDA rose 16.9% to ₹1.54 billion.Order booking for Q3 declined 26% YoY, primarily due to delayed advances on pending orders at quarter-end.US subsidiary recorded a loss of ₹21.7 crore in the first nine months of FY26.Management expects double-digit growth in domestic order bookings in Q4 FY26 driven by steel and cement sectors.First order received for CO2-based heat pumps with an enquiry pipeline currently exceeding 100 units.
👀 கவனிக்க வேண்டியவை
Investors should monitor the conversion of the strong enquiry pipeline into firm orders in Q4 to validate management's growth guidance. The reduction in US duty to 18% and traction in new product segments like heat pumps are positive long-term catalysts despite short-term subsidiary losses.
IFB Industries Q3 FY26: Revenue Up 12% to ₹1,382 Cr, PAT Impacted by Forex and Labor Costs
IFB Industries reported a 12% YoY revenue growth to ₹1,382 crores for Q3 FY26, though PAT declined to ₹24.51 crores from ₹34.36 crores last year. Earnings were pressured by a ₹13.38 crore exceptional charge related to the new Labour Code and significant margin headwinds from forex depreciation and commodity price hikes. Despite these pressures, the company maintained a strong 25%+ market share in front-load washing machines and is targeting ₹79 crores in material cost savings for the full year through efficiency initiatives.
முக்கிய அம்சங்கள்
Q3 Revenue grew 12% YoY to ₹1,382 crores, while PBDIT margins contracted from 7.3% to 5.8%.Forex losses of ₹29 crores and commodity hikes of ₹18 crores YTD largely offset ₹35 crores in cost innovation savings.Recognized an exceptional liability of ₹13.38 crores following the Government of India's Labour Code notification.Front-load washing machine market share remains robust at 25%+, with peak capacity utilization reaching 88-90%.Projected full-year material cost reduction of ₹79 crores via the A&M efficiency program, with ₹35 crores realized YTD.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's ability to recover margins as efficiency projects scale and commodity prices stabilize. While market share in core segments remains strong, the impact of the new Labour Code and forex volatility are key risks to watch in the upcoming quarter.
Ambika Cotton Mills to Expand Capacity to 120,816 Spindles with ₹57 Cr Investment
Ambika Cotton Mills has successfully commissioned 6,048 spindles for specialty yarn and announced a further addition of 6,480 spindles by May 2026. This total expansion of 12,528 spindles will increase the company's total capacity to 120,816 spindles. The project includes solar capacity for captive consumption to manage energy costs. The total investment of ₹57.00 Crores will be funded entirely through internal accruals, reflecting a strong debt-free growth strategy.
முக்கிய அம்சங்கள்
Commissioned 6,048 spindles for specialty yarn production at Dindigul, Tamil NaduProposed addition of 6,480 spindles scheduled for commissioning in May 2026Total spindle capacity to reach 120,816 units following the expansionEstimated project cost of ₹57.00 Crores includes solar power for captive useFunding to be met entirely through internal accruals, maintaining a healthy balance sheet
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive development as the company is expanding its high-margin specialty yarn capacity without taking on debt. Monitor the progress of the May 2026 commissioning for timely execution.
Ambika Cotton Q3 Net Profit Rises 6% YoY to ₹15.17 Cr; Announces ₹57 Cr Capacity Expansion
Ambika Cotton Mills reported a steady Q3 FY26 performance with a Net Profit of ₹15.17 Cr, marking a 6.2% increase from ₹14.28 Cr in the same quarter last year. Revenue from operations grew 11.5% YoY to ₹174.17 Cr, although it saw a sequential decline from ₹199.64 Cr in Q2. The company is aggressively expanding its manufacturing footprint, with a total of 12,528 new spindles being added at a cost of ₹57 Cr. Importantly, this expansion and associated solar power projects are being funded entirely through internal accruals, highlighting strong cash flow management.
முக்கிய அம்சங்கள்
Net Profit for Q3 FY26 stood at ₹15.17 Cr, up from ₹14.28 Cr in Q3 FY25.Revenue from operations increased to ₹174.17 Cr compared to ₹156.26 Cr in the year-ago period.Announced a ₹57 Cr expansion plan to reach a total capacity of 120,816 spindles by May 2026.Expansion is funded via internal accruals, avoiding additional debt burden.Quarterly results were impacted by a foreign currency fluctuation loss of ₹4.14 Cr.
👀 கவனிக்க வேண்டியவை
Investors should take note of the company's ability to fund significant capacity expansion through internal accruals while maintaining profitability. The stock remains a watch for long-term growth as the new spindle capacity comes online in mid-2026.
IFB Industries Appoints Former Tata Steel Executive Tarun Kumar Daga as Independent Director
IFB Industries has appointed Mr. Tarun Kumar Daga as an Additional Non-Executive Independent Director for a two-year term starting February 10, 2026. This appointment follows the completion of Mr. Biswadip Gupta's tenure as an Independent Director on February 9, 2026. Mr. Daga is a seasoned professional with over 35 years of experience, including high-profile roles such as President & CEO of Tata Steel Thailand and Managing Director of The Tinplate Company of India. His extensive background in operations and general management is expected to enhance the board's strategic oversight.
முக்கிய அம்சங்கள்
Appointment of Mr. Tarun Kumar Daga as Independent Director for a 2-year term effective Feb 10, 2026.Cessation of Mr. Biswadip Gupta's directorship on Feb 9, 2026, following the completion of his tenure.Mr. Daga brings over 35 years of industry experience in marketing, sales, and general management.The new director previously served as MD of The Tinplate Company of India for 9 years and CEO of Tata Steel Thailand.Appointment is subject to the approval of the company's members.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive governance move, as the company is replacing a retiring director with a highly experienced professional from the Tata Group. No immediate action is required, but the addition of such expertise is beneficial for long-term strategic planning.
Krebs Biochemicals Q3 Loss Narrows to ₹3.13 Cr; Revenue Declines 36% YoY
Krebs Biochemicals reported a sharp 36.6% YoY decline in revenue from operations to ₹7.27 crore for the quarter ended December 31, 2025. Despite the revenue drop, the company narrowed its net loss to ₹3.13 crore from ₹7.74 crore in the previous year's corresponding quarter, largely due to a significant reduction in operating expenses. A major operational headwind persists as the Vizag manufacturing unit remains closed following a February 2025 order from the Andhra Pradesh Pollution Control Board. The company's financial position is critical, with a negative net worth of ₹160.83 crore and total borrowings exceeding ₹221 crore.
முக்கிய அம்சங்கள்
Revenue from operations fell to ₹727.42 lacs in Q3 FY26 compared to ₹1,146.72 lacs in Q3 FY25.Net loss for the quarter narrowed to ₹312.65 lacs from ₹773.89 lacs YoY.Total expenses were reduced by approximately 46% YoY to ₹1,040.49 lacs.The Vizag manufacturing unit remains shut down since February 7, 2025, due to regulatory orders.Company reports a deeply negative net worth of ₹16,083.25 lacs as of December 31, 2025.
👀 கவனிக்க வேண்டியவை
Investors should remain highly cautious as the company faces severe financial distress with negative net worth and ongoing regulatory issues at its Vizag plant. The significant drop in revenue and high debt levels make this a high-risk situation despite the narrowing of quarterly losses.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
